DMD and hemophilia B: Elevations in liver enzyme levels were reported as SAEs after clinical vector administration in clinical trials for DMD (n = 2), hemophilia A (n = 2), hemophilia B (n = 3), mucopolysaccharidosis (MPS) type IIIB (n = 1), and SMA (n = 4).